Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates.

Islam MM, Tan Y, Hameed HMA, Liu Z, Chhotaray C, Liu Y, Lu Z, Cai X, Tang Y, Gao Y, Surineni G, Li X, Tan S, Guo L, Cai X, Yew WW, Liu J, Zhong N, Zhang T.

Clin Microbiol Infect. 2018 Dec 22. pii: S1198-743X(18)30794-8. doi: 10.1016/j.cmi.2018.12.008. [Epub ahead of print]

PMID:
30583053
2.

Management of adverse reactions to high-dose moxifloxacin used in multidrug-resistant tuberculosis treatment programmes.

Yew WW, Chang KC.

Respirology. 2018 Dec 6. doi: 10.1111/resp.13452. [Epub ahead of print] Review. No abstract available.

3.

Can modulating redox status help to enhance antituberculosis drug efficacy?

Yew WW, Chang KC, Chan DP, Zhang Y.

Tuberculosis (Edinb). 2018 Dec;113:177-178. doi: 10.1016/j.tube.2018.10.002. Epub 2018 Oct 9. No abstract available.

PMID:
30514500
4.

Vitamin C and Mycobacterium tuberculosis Persisters.

Yew WW, Chang KC, Leung CC, Chan DP, Zhang Y.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01641-18. doi: 10.1128/AAC.01641-18. Print 2018 Nov. No abstract available.

PMID:
30355747
5.

Erratum for Yew et al., "Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity".

Yew WW, Chang KC, Chan DP.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01633-18. doi: 10.1128/AAC.01633-18. Print 2018 Oct. No abstract available.

6.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
7.

Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv.

Mugweru J, Liu J, Makafe G, Chiwala G, Wang B, Wang C, Li X, Tan Y, Yew WW, Tan S, Zhang T.

Infect Drug Resist. 2018 Jun 13;11:891-894. doi: 10.2147/IDR.S163965. eCollection 2018.

8.

Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.

Yew WW, Chang KC, Chan DP.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e02637-17. doi: 10.1128/AAC.02637-17. Print 2018 Aug. Review. Erratum in: Antimicrob Agents Chemother. 2018 Sep 24;62(10):.

9.

Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Hameed HMA, Islam MM, Chhotaray C, Wang C, Liu Y, Tan Y, Li X, Tan S, Delorme V, Yew WW, Liu J, Zhang T.

Front Cell Infect Microbiol. 2018 Apr 10;8:114. doi: 10.3389/fcimb.2018.00114. eCollection 2018. Review.

10.

Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.

Chang KC, Leung EC, Law WS, Leung WM, Tai LB, Lee SN, Lam FM, Chau CH, Mok TY, Yew WW, Leung CC.

Eur Respir J. 2018 Jun 14;51(6). pii: 1800159. doi: 10.1183/13993003.00159-2018. Print 2018 Jun. No abstract available.

PMID:
29650556
11.

Epidemiological, clinical and mechanistic perspectives of tuberculosis in older people.

Yew WW, Yoshiyama T, Leung CC, Chan DP.

Respirology. 2018 Jun;23(6):567-575. doi: 10.1111/resp.13303. Epub 2018 Apr 1. Review.

12.

RE: "DIETARY INTAKE OF ANTIOXIDANT VITAMINS AND CAROTENOIDS AND RISK OF DEVELOPING ACTIVE TUBERCULOSIS IN A PROSPECTIVE POPULATION-BASED COHORT".

Yew WW, Chan DP, Leung CC, Zhang Y.

Am J Epidemiol. 2018 Jul 1;187(7):1570-1571. doi: 10.1093/aje/kwx381. No abstract available.

PMID:
29370338
13.

Does oxidative stress contribute to adverse outcomes in HIV-associated TB?

Yew WW, Chan DP, Singhal A, Zhang Y, Lee SS.

J Antimicrob Chemother. 2018 May 1;73(5):1117-1120. doi: 10.1093/jac/dkx509.

PMID:
29325139
14.

Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?

Chang KC, Yew WW, Zhang Y.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01907-17. doi: 10.1128/AAC.01907-17. Print 2018 Jan. No abstract available.

15.

Supramolecular strategy for reducing the cardiotoxicity of bedaquiline without compromising its antimycobacterial efficacy.

Kuok KI, In Ng PC, Ji X, Wang C, Yew WW, Chan DPC, Zheng J, Lee SMY, Wang R.

Food Chem Toxicol. 2018 Sep;119:425-429. doi: 10.1016/j.fct.2017.12.022. Epub 2017 Dec 16.

PMID:
29258954
16.

Molecular mechanisms of clofazimine resistance in Mycobacterium tuberculosis.

Yew WW, Liang D, Chan DP, Shi W, Zhang Y.

J Antimicrob Chemother. 2017 Oct 1;72(10):2943-2944. doi: 10.1093/jac/dkx227. No abstract available.

PMID:
29091204
17.

Can toxicities induced by antituberculosis drugs be better managed in diabetic patients?

Yew WW, Chan DP, Leung CC, Zhang Y, Wang R, Ng P, Lee SM.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700409. doi: 10.1183/13993003.00409-2017. Print 2017 Jul. No abstract available.

18.

Nontuberculous Mycobacteria Infections at a Provincial Reference Hospital, Cambodia.

Bonnet M, San KC, Pho Y, Sok C, Dousset JP, Brant W, Hurtado N, Eam KK, Ardizzoni E, Heng S, Godreuil S, Yew WW, Hewison C.

Emerg Infect Dis. 2017 Jul;23(7):1139-1147. doi: 10.3201/eid2307.170060.

19.

Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.

Njire M, Wang N, Wang B, Tan Y, Cai X, Liu Y, Mugweru J, Guo J, Hameed HMA, Tan S, Liu J, Yew WW, Nuermberger E, Lamichhane G, Liu J, Zhang T.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00070-17. doi: 10.1128/AAC.00070-17. Print 2017 Jul.

20.

Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis.

Leung CC, Yew WW, Mok TYW, Lau KS, Wong CF, Chau CH, Chan CK, Chang KC, Tam G, Tam CM.

Respirology. 2017 Aug;22(6):1225-1232. doi: 10.1111/resp.13017. Epub 2017 Feb 28.

PMID:
28244689
21.

Oxidative stress and TB outcomes in patients with diabetes mellitus?

Yew WW, Leung CC, Zhang Y.

J Antimicrob Chemother. 2017 Jun 1;72(6):1552-1555. doi: 10.1093/jac/dkx046.

PMID:
28204508
22.

Drug resistance mechanisms and novel drug targets for tuberculosis therapy.

Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T.

J Genet Genomics. 2017 Jan 20;44(1):21-37. doi: 10.1016/j.jgg.2016.10.002. Epub 2016 Oct 11. Review.

PMID:
28117224
23.

Complexation of clofazimine by macrocyclic cucurbit[7]uril reduced its cardiotoxicity without affecting the antimycobacterial efficacy.

Li S, Chan JY, Li Y, Bardelang D, Zheng J, Yew WW, Chan DP, Lee SM, Wang R.

Org Biomol Chem. 2016 Aug 21;14(31):7563-9. doi: 10.1039/c6ob01060a. Epub 2016 Jul 21.

PMID:
27439674
24.

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy.

Mieras L, Anthony R, van Brakel W, Bratschi MW, van den Broek J, Cambau E, Cavaliero A, Kasang C, Perera G, Reichman L, Richardus JH, Saunderson P, Steinmann P, Yew WW.

Infect Dis Poverty. 2016 Jun 8;5(1):46. doi: 10.1186/s40249-016-0140-y. Review.

25.

Update on pulmonary disease due to non-tuberculous mycobacteria.

Stout JE, Koh WJ, Yew WW.

Int J Infect Dis. 2016 Apr;45:123-34. doi: 10.1016/j.ijid.2016.03.006. Epub 2016 Mar 11. Review.

26.

Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

Makafe GG, Cao Y, Tan Y, Julius M, Liu Z, Wang C, Njire MM, Cai X, Liu T, Wang B, Pang W, Tan S, Zhang B, Yew WW, Lamichhane G, Guo J, Zhang T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3202-6. doi: 10.1128/AAC.00152-16. Print 2016 May.

27.

Genome-guided Investigation of Antibiotic Substances produced by Allosalinactinospora lopnorensis CA15-2(T) from Lop Nor region, China.

Huang C, Leung RK, Guo M, Tuo L, Guo L, Yew WW, Lou I, Lee SM, Sun C.

Sci Rep. 2016 Feb 11;6:20667. doi: 10.1038/srep20667.

28.

Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.

Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, Chan D, Yew WW, Zhang W, Zhang Y.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2542-4. doi: 10.1128/AAC.02941-15. Print 2016 Apr.

29.

Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?

Yew WW, Koh WJ.

Korean J Intern Med. 2016 Jan;31(1):15-29. doi: 10.3904/kjim.2016.31.1.15. Epub 2015 Dec 28. Review.

30.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
31.

Clinical research in the treatment of tuberculosis: current status and future prospects.

Chang KC, Yew WW, Sotgiu G.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1417-27. doi: 10.5588/ijtld.15.0216. Review.

PMID:
26614181
32.

Concurrent Outbreaks of Tuberculosis in a School and the Wider Community in Macau.

Chou KH, Kam KM, Ieong SK, Yip CW, Ip PK, Yew WW, Leung CC, Wong NS, Lau SM, Lee SS.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):359-62. doi: 10.1093/jpids/piu031. Epub 2014 Apr 30.

PMID:
26582875
33.

Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.

Zhang Y, Yew WW.

Int J Tuberc Lung Dis. 2015 Nov;19(11):1276-89. doi: 10.5588/ijtld.15.0389. Review.

PMID:
26467578
34.

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

Ho PL, Yam WC, Leung CC, Yew WW, Mok TY, Chan KS, Tam CM.

Hong Kong Med J. 2015 Jun;21 Suppl 4:4-7. No abstract available.

35.

Are pulmonary non-tuberculous mycobacteria of concern in the Western Pacific Region?

Yew WW, Chiang CY, Lumb R, Islam T.

Int J Tuberc Lung Dis. 2015 May;19(5):499-500. doi: 10.5588/ijtld.15.0118. No abstract available.

PMID:
25868014
36.

Expanding the evidence base supporting shorter treatment durations for multidrug-resistant tuberculosis.

Nuermberger E, Yew WW.

Int J Tuberc Lung Dis. 2015 May;19(5):497-8. doi: 10.5588/ijtld.15.0110. No abstract available.

PMID:
25868013
37.

Western Pacific Regional Green Light Committee: progress and way forward.

Islam T, Marais BJ, Nhung NV, Chiang CY, Yew WW, Yoshiyama T, Mira NR, van den Broek J, Lumb R, Nishikiori N, Reichman LB.

Int J Infect Dis. 2015 Mar;32:161-5. doi: 10.1016/j.ijid.2015.01.001.

38.

T-Spot.TB outperforms tuberculin skin test in predicting development of active tuberculosis among household contacts.

Leung CC, Yam WC, Ho PL, Yew WW, Chan CK, Law WS, Lee SN, Chang KC, Tai LB, Tam CM.

Respirology. 2015 Apr;20(3):496-503. doi: 10.1111/resp.12483. Epub 2015 Feb 17.

39.

Novel drugs against tuberculosis: a clinician's perspective.

Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC.

Eur Respir J. 2015 Apr;45(4):1119-31. doi: 10.1183/09031936.00162314. Epub 2014 Nov 27. Review.

40.

Smoking adversely affects treatment response, outcome and relapse in tuberculosis.

Leung CC, Yew WW, Chan CK, Chang KC, Law WS, Lee SN, Tai LB, Leung EC, Au RK, Huang SS, Tam CM.

Eur Respir J. 2015 Mar;45(3):738-45. doi: 10.1183/09031936.00114214. Epub 2014 Oct 30.

41.

Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.

Koh WJ, Stout JE, Yew WW.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1141-8. doi: 10.5588/ijtld.14.0134. Review.

PMID:
25216826
42.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB.

Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.

43.

Linezolid in the treatment of drug-resistant tuberculosis: the way forward?

Yew WW, Lange C.

Int J Tuberc Lung Dis. 2014 Jun;18(6):631-2. doi: 10.5588/ijtld.14.0191. No abstract available.

PMID:
24903928
44.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET.

Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.

45.

Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt?

Yew WW, Lange C.

Int J Tuberc Lung Dis. 2014 Jan;18(1):1-2. doi: 10.5588/ijtld.13.0739. No abstract available.

PMID:
24365543
46.

WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Chang KC, Yew WW, Tam CM, Leung CC.

Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104. doi: 10.1128/AAC.00120-13. Epub 2013 Jun 17. Review.

47.

High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward?

Yew WW, Nuermberger E.

Int J Tuberc Lung Dis. 2013 Jul;17(7):853-4. doi: 10.5588/ijtld.13.0301. No abstract available.

PMID:
23743304
48.

In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.

Yip PC, Kam KM, Lam ET, Chan RC, Yew WW.

Int J Antimicrob Agents. 2013 Jul;42(1):96-7. doi: 10.1016/j.ijantimicag.2013.03.002. Epub 2013 May 15. No abstract available.

PMID:
23684005
49.

Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis?

Chang KC, Sterling TR, Yew WW.

Int J Tuberc Lung Dis. 2013 Jun;17(6):712. doi: 10.5588/ijtld.13.0120. No abstract available.

PMID:
23676152
50.

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Chang KC, Yew WW, Cheung SW, Leung CC, Tam CM, Chau CH, Wen PK, Chan RC.

Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.

Supplemental Content

Support Center